200 related articles for article (PubMed ID: 9744346)
1. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy.
Virgolini I; Kurtaran A; Leimer M; Kaserer K; Peck-Radosavljevic M; Angelberger P; Hübsch P; Dvorak M; Valent P; Niederle B
J Nucl Med; 1998 Sep; 39(9):1575-9. PubMed ID: 9744346
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
[TBL] [Abstract][Full Text] [Related]
3. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
[TBL] [Abstract][Full Text] [Related]
4. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.
Raderer M; Kurtaran A; Yang Q; Meghdadi S; Vorbeck F; Hejna M; Angelberger P; Kornek G; Pidlich J; Scheithauer W; Virgolini I
J Nucl Med; 1998 Sep; 39(9):1570-5. PubMed ID: 9744345
[TBL] [Abstract][Full Text] [Related]
5. VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.
Nakayama S; Yokote T; Kobayashi K; Hirata Y; Hiraiwa T; Komoto I; Miyakoshi K; Yamakawa Y; Takubo T; Tsuji M; Imamura M; Hanafusa T
Endocrine; 2009 Apr; 35(2):143-6. PubMed ID: 19184565
[TBL] [Abstract][Full Text] [Related]
6. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
Reubi JC
J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054
[TBL] [Abstract][Full Text] [Related]
7. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Yang Q; Radosavljevic M; Leimer M; Kaserer K; Li SR; Kornek G; Hübsch P; Niederle B; Pidlich J; Scheithauer W; Valent P
Nucl Med Biol; 1996 Aug; 23(6):685-92. PubMed ID: 8940711
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours.
Hessenius C; Bäder M; Meinhold H; Böhmig M; Faiss S; Reubi JC; Wiedenmann B
Eur J Nucl Med; 2000 Nov; 27(11):1684-93. PubMed ID: 11105825
[TBL] [Abstract][Full Text] [Related]
9. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.
Raderer M; Kurtaran A; Leimer M; Angelberger P; Niederle B; Vierhapper H; Vorbeck F; Hejna MH; Scheithauer W; Pidlich J; Virgolini I
J Clin Oncol; 2000 Mar; 18(6):1331-6. PubMed ID: 10715305
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide-secreting tumors.
Thomason JW; Martin RS; Fincher ME
Clin Nucl Med; 2000 Sep; 25(9):661-4. PubMed ID: 10983749
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
12. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin in preoperative therapy and postoperative diagnosis of a patient with Verner Morrison syndrome].
Weinel RJ; Neuhaus C; Stapp J; Klotter HJ; Trautmann ME; Arnold R; Josef K; Rothmund M
Langenbecks Arch Chir; 1992; 377(6):345-7. PubMed ID: 1282641
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
Reubi JC; Waser B; Laissue JA; Gebbers JO
Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
[TBL] [Abstract][Full Text] [Related]
15. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
[TBL] [Abstract][Full Text] [Related]
16. VIPoma syndrome.
Krejs GJ
Am J Med; 1987 May; 82(5B):37-48. PubMed ID: 3035922
[TBL] [Abstract][Full Text] [Related]
17. In vitro release of vasoactive intestinal polypeptide and pancreatic polypeptide from human VIPoma cells and its inhibition by somatostatin analogue (SMS 201-995).
Yasunami Y; Funakoshi A; Ryu S; Shinozaki H; Jimi A; Miyazaki K; Ikeda S
Surgery; 1994 Jun; 115(6):713-7. PubMed ID: 8197564
[TBL] [Abstract][Full Text] [Related]
18. [123I]VIP receptor scintigraphy in patients with pancreatic adenocarcinomas.
Eisenhut M; Haberkorn U
Eur J Nucl Med; 2000 Nov; 27(11):1589-90. PubMed ID: 11105813
[No Abstract] [Full Text] [Related]
19. Vasoactive intestinal peptide receptor scintigraphy.
Virgolini I; Kurtaran A; Raderer M; Leimer M; Angelberger P; Havlik E; Li S; Scheithauer W; Niederle B; Valent P
J Nucl Med; 1995 Oct; 36(10):1732-9. PubMed ID: 7562036
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.
Nilubol N; Freedman EM; Quezado MM; Patel D; Kebebew E
J Clin Endocrinol Metab; 2016 Oct; 101(10):3564-3567. PubMed ID: 27583474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
